Coya Therapeutics (NASDAQ:COYA) Posts Earnings Results, Beats Expectations By $0.07 EPS

Coya Therapeutics (NASDAQ:COYA) issued its quarterly earnings data on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.07, Zacks reports. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%.The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million.

Coya Therapeutics Stock Down 2.1%

NASDAQ COYA traded down $0.10 on Wednesday, reaching $4.70. 31,315 shares of the stock traded hands, compared to its average volume of 193,164. Coya Therapeutics has a 12 month low of $3.71 and a 12 month high of $7.75. The company has a market cap of $110.26 million, a price-to-earnings ratio of -4.09 and a beta of 0.60. The firm’s fifty day simple moving average is $4.86 and its 200 day simple moving average is $4.67.

Institutional Trading of Coya Therapeutics

Several institutional investors have recently modified their holdings of COYA. XTX Topco Ltd bought a new position in Coya Therapeutics during the fourth quarter valued at about $192,000. Occudo Quantitative Strategies LP acquired a new stake in Coya Therapeutics in the 4th quarter valued at about $66,000. Millennium Management LLC acquired a new stake in Coya Therapeutics in the 4th quarter valued at about $121,000. 683 Capital Management LLC bought a new position in shares of Coya Therapeutics during the 4th quarter valued at about $465,000. Finally, Cetera Investment Advisers bought a new position in shares of Coya Therapeutics during the 4th quarter valued at about $128,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

Trending Headlines about Coya Therapeutics

Here are the key news stories impacting Coya Therapeutics this week:

• Positive Sentiment: Chardan Capital reaffirmed its Buy rating and set a $14.00 price target, implying approximately 196% upside from the reference price of $4.73. The bullish target is based on expectations for substantial long-term value creation. Chardan Capital rating report
• Positive Sentiment: Roth MKM also reaffirmed its Buy rating, adding to the favorable analyst sentiment surrounding COYA. Roth MKM rating report
• Positive Sentiment: Coya reported a second-quarter loss of $0.28 per share, better than the $0.35 consensus estimate, while revenue of $0.24 million exceeded expectations of $0.13 million. The beat may provide modest support for the shares. Coya second-quarter results
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day short-interest ratio. Because the data also showed an undefined percentage change, it offers little reliable information about short-selling pressure or potential covering activity.
• Negative Sentiment: Despite the quarterly beat, Coya remains unprofitable, with a negative net margin and return on equity. Analysts expect a full-year loss of approximately $1.49 per share, so future clinical progress and funding needs remain important risks for investors.

Analyst Ratings Changes

Several analysts recently commented on the company. Wall Street Zen cut Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Chardan Capital reissued a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a report on Friday, July 17th. Finally, Roth Capital began coverage on shares of Coya Therapeutics in a research note on Friday, June 5th. They set a “buy” rating and a $12.00 price objective on the stock. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $15.33.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.